WO2024075075 - COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE
National phase entry:
Publication Number
WO/2024/075075
Publication Date
11.04.2024
International Application No.
PCT/IB2023/060055
International Filing Date
06.10.2023
Title **
[English]
COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE
[French]
COMPOSÉS, COMPOSITIONS ET MÉTHODES DE TRAITEMENT D'UNE MALADIE INTESTINALE INFLAMMATOIRE
Applicants **
RENEXXION IRELAND LIMITED
Inventors
MILNER, Peter Gerard
DRUZGALA, Pascal
SOARES, Luis
BECKER, Cyrus, K.
Priority Data
63/378,667
06.10.2022
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2990 | |
| EPO | Filing, Examination, Granting | 20623 | |
| Japan | Filing, Examination, Granting | 2849 | |
| South Korea | Filing, Examination, Granting | 3598 | |
| USA | Filing, Examination, Granting | 10740 |
Total:
40,800
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Protein-drug conjugates and variants thereof that treat inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis. The protein-drug conjugates (PDC) have a fusion protein having a thioredoxin protein and an IL22 protein or variant/mutein thereof, wherein a drug laquinimod (or derivative thereof) is conjugated to the thioredoxin, and wherein the laquinimod is cleavable from the fusion protein upon being deposited within an intestinal epithelial cell or an intestinal epithelial stem cells.[French]
L'invention concerne des conjugués protéine-médicament et des variants de ceux-ci qui traitent une maladie inflammatoire chronique de l'intestin (MICI), notamment la maladie de Crohn et la colite ulcéreuse. Les conjugués protéine-médicament (PDC) ont une protéine de fusion ayant une protéine thiorédoxine et une protéine IL22 ou un variant/mutéine de celle-ci, un médicament, le laquinimod, (ou un dérivé de celui-ci) étant conjugué à la thiorédoxine, et le laquinimod pouvant être clivé à partir de la protéine de fusion lorsqu'il est déposé à l'intérieur d'une cellule épithéliale intestinale ou d'une cellule souche épithéliale intestinale.